Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.49 |
| ▸ | CALCRL | Q16602 | 9/20 | 0.48 |
| ▸ | CTSS | P25774 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279615 | 0.92 | BRD4 (0.50) | CALCRLCTSSCHRM4RAMP1 | |
| SCHEMBL3964481 | 0.87 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OGFRL1CALCRL | |
| SCHEMBL13801369 | 0.86 | OPRM1 (0.48) | OPRM1OPRD1OPRK1OGFRL1CALCRL | |
| SCHEMBL14410235 | 0.84 | CALCRL (0.51) | OPRM1OPRD1OPRK1OGFRL1CALCRL | |
| SCHEMBL2872824 | 0.83 | BRD4 (0.56) | CALCRLCTSSCHRM4RAMP1 | |
| SCHEMBL13313600 | 0.82 | BRD4 (0.57) | CALCRLCTSSCHRM4RAMP1 | |
| SCHEMBL3967246 | 0.82 | CHRM4 (0.65) | CALCRLCTSSCHRM4RAMP1 | |
| SCHEMBL3278838 | 0.81 | CALCRL (0.44) | CALCRLCTSSRAMP1 | |
| SCHEMBL12400687 | 0.81 | CHRM4 (0.50) | CALCRLCTSSCHRM4RAMP1 | |
| SCHEMBL14410234 | 0.80 | CALCRL (0.50) | OPRM1OPRD1OPRK1OGFRL1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | claimed |
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | OPRM1 18/4885OPRD1 31/4885OPRK1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.